Form 990 for tax year 2022
Filed by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC.
Totals
- Total revenue
- $45,044,474
- Total expenses
- $38,280,730
- Contributions and grants received
- $42,022,114
- Grants paid
- $4,589,741
- Program service revenue
- $2,152,800
- Investment income
- $670,999
- Other revenue
- $198,561
- Total assets, end of year
- $89,097,661
- Total liabilities, end of year
- $25,407,747
- Net assets or fund balances, end of year
- $63,689,914
- Program services expenses (Part IX)
- $32,231,243
- Management and general expenses
- $1,151,462
- Fundraising expenses
- $4,898,025
- Program service expenses (Part III)
- $32,231,243
Program services were 84.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1f · All other contributions, gifts and grants
$42,022,114
-
1g · Noncash contributions included above
$191,034
-
2a · Program service revenue: RESEARCH & CLINICAL TRIALS
total $2,152,800 · related or exempt $2,152,800
-
3 · Investment income
total $679,638 · excluded $679,638
-
5 · Royalties
total $192,561 · related or exempt $192,561
-
7a · Gross sales of assets other than inventory
securities $93,023,508
-
7b · Less cost or other basis and sales expenses
securities $93,032,147
-
7c · Gain or loss
securities -$8,639
-
7d · Net gain or loss
total -$8,639 · excluded -$8,639
-
11a · Other revenue: OTHER INCOME
total $6,000 · excluded $6,000
-
11e · Other revenue, total
$6,000
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $4,532,241 · program services $4,532,241
-
3 · Grants to foreign organizations and individuals
total $57,500 · program services $57,500
-
5 · Compensation of officers, directors and key employees
total $3,961,065 · program services $2,799,433 · management and general $372,096 · fundraising $789,536
-
7 · Other salaries and wages
total $5,211,096 · program services $3,682,879 · management and general $489,521 · fundraising $1,038,696
-
8 · Pension plan contributions
total $170,487 · program services $120,490 · management and general $16,015 · fundraising $33,982
-
9 · Other employee benefits
total $404,960 · program services $286,201 · management and general $38,041 · fundraising $80,718
-
10 · Payroll taxes
total $627,329 · program services $443,357 · management and general $58,930 · fundraising $125,042
-
11a · Fees: management
total $1,050,024 · program services $933,603 · management and general $20,547 · fundraising $95,874
-
11b · Fees: legal
total $116,025 · program services $101,769 · management and general $3,662 · fundraising $10,594
-
11c · Fees: accounting
total $60,200 · program services $52,803 · management and general $1,900 · fundraising $5,497
-
11g · Fees: other
total $8,270,865 · program services $7,192,987 · management and general $34,487 · fundraising $1,043,391
-
12 · Advertising and promotion
total $845,594 · program services $546,766 · management and general $26,688 · fundraising $272,140
-
13 · Office expenses
total $1,475,787 · program services $1,331,614 · management and general $4,201 · fundraising $139,972
-
14 · Information technology
total $1,404,775 · program services $1,232,174 · management and general $44,336 · fundraising $128,265
-
16 · Occupancy
total $227,995 · program services $199,982 · management and general $7,196 · fundraising $20,817
-
17 · Travel
total $647,770 · program services $421,737 · management and general $4,580 · fundraising $221,453
-
19 · Conferences, conventions and meetings
total $886,269 · program services $36,263 · fundraising $850,006
-
22 · Depreciation, depletion and amortization
total $951,835 · program services $900,195 · management and general $24,211 · fundraising $27,429
-
23 · Insurance
total $160,043 · program services $140,379 · management and general $5,051 · fundraising $14,613
-
24a · Other expenses: CLINICAL TRIALS
total $6,644,828 · program services $6,644,828
-
24b · Other expenses: TISSUE BANKING
total $574,042 · program services $574,042
-
26 · Joint costs (an allocation of the lines above)
total $192,371 · program services $95,308 · management and general $0 · fundraising $97,063
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $13,953,290 · end of year $5,060,628
-
2 · Savings and temporary cash investments
beginning of year $21,392,706 · end of year $13,092,430
-
3 · Pledges and grants receivable
beginning of year $5,289,425 · end of year $5,229,372
-
4 · Accounts receivable
beginning of year $7,335,350 · end of year $8,274,610
-
9 · Prepaid expenses and deferred charges
beginning of year $225,493 · end of year $896,043
-
10a · Land, buildings and equipment: cost or other basis
$6,732,447
-
10b · Land, buildings and equipment: accumulated depreciation
$3,768,321
-
10c · Land, buildings and equipment, net
beginning of year $1,816,801 · end of year $2,964,126
-
11 · Investments: publicly traded securities
beginning of year $29,648,577 · end of year $41,091,535
-
13 · Investments: program-related
beginning of year $5,648,228 · end of year $11,719,698
-
15 · Other assets
beginning of year $91,977 · end of year $769,219
-
17 · Accounts payable and accrued expenses
beginning of year $12,252,194 · end of year $15,173,286
-
18 · Grants payable
beginning of year $3,265,756 · end of year $43,261
-
19 · Deferred revenue
beginning of year $12,157,093 · end of year $9,131,077
-
25 · Other liabilities
beginning of year $492,004 · end of year $1,060,123
-
27 · Net assets without donor restrictions
beginning of year $45,234,580 · end of year $56,121,149
-
28 · Net assets with donor restrictions
beginning of year $12,000,220 · end of year $7,568,765
Mission and programs · 2022
Mission
SEE SCHEDULE O
-
THE IMMUNE SYSTEM IS A CRITICAL FACTOR IN MYELOMA PROGNOSIS AND TREATMENT BECAUSE IT CAN DETECT AND DESTROY ABNORMAL CELLS, INCLUDING CANCER CELLS. TO ADVANCE OUR UNDERSTANDING OF HOW A MYELOMA PATIENT'S IMMUNE SYSTEM CHANGES DURING THE DEVELOPMENT OF THEIR DISEASE AND HOW IT IS AFFECTED BY THERAPY, WE ARE DEVELOPING AN IMMUNE FOCUSED DATABASE, CALLED THE MMRF IMMUNE ATLAS. IT UTILIZES PATIENT SAMPLES AND CLINICAL DATA FROM OUR GROUNDBREAKING COMMPASS STUDY - ONE OF THE LARGEST MYELOMA DATASETS IN THE PUBLIC DOMAIN. THE IMMUNE ATLAS IS DESIGNED TO DESCRIBE THE MYELOMA PATIENT IMMUNE SYSTEM FROM DISEASE DEVELOPMENT, THROUGH DIAGNOSIS, AND THE TREATMENT JOURNEY. THE INFORMATION, COLLECTED FROM HUNDREDS OF PATIENTS, WILL BE COMBINED WITH THE EXISTING GENOMIC AND CLINICAL DATA FROM COMMPASS TO DEVELOP A MORE COMPREHENSIVE PICTURE OF MYELOMA DISEASE BIOLOGY. THE INSIGHTS GENERATED THROUGH IMMUNE ATLAS WILL HELP GUIDE OPTIMAL TREATMENT APPROACHES FOR MYELOMA PATIENTS IN THE FUTURE.
Expenses $7,028,145 · Grants $1,363,694 · Revenue $2,345,361
-
THE MMRF CURECLOUD IS A FIRST-OF-ITS-KIND REGISTRY THAT COLLECTS GENOMIC AND CLINICAL INFORMATION TO INFORM BETTER TREATMENTS FOR PATIENTS. THE AGGREGATED DATA IS ALSO DESIGNED TO HELP RESEARCHERS DISCOVER NEW TARGETS FOR MYELOMA AND FORM HYPOTHESES FOR CLINICAL TRIALS.PATIENTS PARTICIPATING IN CURECLOUD CONTRIBUTE A BLOOD SAMPLE THAT IS SENT TO A CENTRAL LAB FOR DNA SEQUENCING. THIS SEQUENCING DATA IS COMBINED WITH THE PATIENT'S MEDICAL RECORDS TO PROVIDE A BETTER UNDERSTANDING OF THEIR DISEASE HISTORY. ALL PATIENT DATA STORED IN CURECLOUD IS THEN ANONYMIZED, AGGREGATED, AND WILL BE SHARED WITH RESEARCHERS AND MEDICAL PROFESSIONALS. TO DATE, MORE THAN 1,000 PATIENTS HAVE ENROLLED. IN THE FALL OF 2022, TWO PATIENT REPORTED OUTCOME (PRO) SURVEYS WERE ADMINISTERED TO CURECLOUD PARTICIPANTS IN ORDER TO TRACK PATIENT EXPERIENCES WITH MYELOMA THERAPY OVER TIME AND ACROSS TREATMENTS. THE CANCER THERAPY SATISFACTION QUESTIONNAIRE MEASURED EXPECTATIONS OF THERAPY, FEELINGS ABOUT SIDE EFFECTS, AND SATISFACTION WITH CANCER THERAPY. THE FACIT COST SURVEY MEASURED THE FINANCIAL IMPACT RELATED TO THERAPY EXPERIENCED BY MYELOMA PATIENTS. CURECLOUD WILL BE CLOSING PATIENT ENROLLMENT AT THE END OF 2023.
Expenses $3,226,047 · Grants $3,226,047
-
THE MULTIPLE MYELOMA RESEARCH CONSORTIUM (MMRC) IS A NETWORK OF LEADING MYELOMA TREATMENT CENTERS THAT CONDUCT EARLY-STAGE CLINICAL TRIALS TO EVALUATE NOVEL TREATMENT STRATEGIES FOR PATIENTS. THIS COLLABORATIVE RESEARCH MODEL HAS CONDUCTED CLOSE TO 100 PHASE I AND PHASE II CLINICAL TRIALS, ENROLLING OVER A THOUSAND PATIENTS TO DATE. THE MMRC CONTINUES TO SUCCESSFULLY FOSTER THE DEVELOPMENT OF NOVEL THERAPIES AND CHAMPION RIGOROUS RESEARCH AND CLINICAL TRIALS. CURRENT MMRC CLINICAL TRIALS THAT HAVE THE POTENTIAL TO MAKE SIGNIFICANT CONTRIBUTIONS FOR MYELOMA TREATMENT INCLUDE: MYDRUGTHE MMRF MYDRUG STUDY IS THE FIRST PLATFORM TRIAL IN MYELOMA. THE PURPOSE OF MYDRUG IS TO TEST TARGETED THERAPIES NOT YET APPROVED IN MYELOMA, IN COMBINATION WITH A STANDARD OF CARE ORAL TRIPLET THERAPY, IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA PATIENTS WHO DEMONSTRATE SPECIFIC GENETIC ALTERATIONS. IT IS EVALUATING TREATMENTS THAT ARE TARGETED AGAINST SPECIFIC GENOMIC ALTERATIONS WITHIN THE MYELOMA CELLS.THE SCIENTIFIC HYPOTHESIS FOR THE MYDRUG CLINICAL TRIAL CAME OUT OF OUR COMMPASS STUDY, WHICH HAS GENERATED THE LARGEST MYELOMA GENOMICS DATABASE OPENLY ACCESSIBLE TO RESEARCHERS ACROSS THE GLOBE. THE MYDRUG STUDY IS EXPECTED TO CLOSE NEW ENROLLMENTS IN 2024. ELO-IBER (RELAPSED/REFRACTORY)IBERDOMIDE (CC-220) IS A NEW AND POTENTIALLY MORE POTENT MEMBER OF A CLASS OF MEDICINES KNOWN AS IMMUNOMODULATORS (IMIDS), WHICH INCLUDES REVLIMID (LENALIDOMIDE) AND POMALYST (POMALIDOMIDE). THIS IS A PHASE 1B/2 STUDY THAT WILL HELP DETERMINE THE OPTIMAL DOSE OF IBERDOMIDE THAT CAN BE GIVEN TO PATIENTS - IN COMBINATION WITH EMPLICITI (ELOTUZUMAB) AND DEXAMETHASONE - THAT IS SAFE AND HAS THE FEWEST SIDE EFFECTS. ARCELLX (RELAPSED/REFRACTORY)CART-DDBCMA IS A CAR-T CELL THERAPY CANDIDATE THAT USES PATIENT T CELLS THAT HAVE BEEN GENETICALLY MODIFIED TO RECOGNIZE AND KILL MYELOMA CELLS. THIS NEWER VERSION OF CAR-T CELL THERAPY IS DESIGNED TO FORM A STRONGER BOND TO BCMA, A COMMON TARGET FOR MYELOMA TREATMENT, AND KILL MYELOMA CELLS MORE EFFICIENTLY THAN PREVIOUS THERAPIES. BEIGENE (RELAPSED/REFRACTORY)THIS PHASE I/II STUDY IS EVALUATING HOW SAFE AND EFFECTIVE A NEW TARGETED THERAPY (BGB-11417) IS ALONE, AND IN COMBINATION WITH KYPROLIS (CARFILZOMIB) AND DEXAMETHASONE, IN PEOPLE WITH RELAPSED OR REFRACTORY MYELOMA. BGB-11417 IS A BCL-2 INHIBITOR THAT IS POTENTIALLY EFFECTIVE IN MYELOMA PATIENTS WITH THE 11;14 CHROMOSOMAL TRANSLOCATION, WHICH ACCOUNTS FOR ABOUT 20% OF PATIENTS. SARCAR IST THIS TRIAL WILL DETERMINE THE SIDE EFFECTS AND BEST DOSE OF SARCLISA (ISATUXIMAB) WHEN GIVEN TOGETHER WITH CARFILZOMIB WITH OR WITHOUT DEXAMETHASONE AND LENALIDOMIDE IN TREATING PATIENTS WITH RELAPSED/REFRACTORY MYELOMA. IN ARM 1, IT WILL DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF SARCLISA IN COMBINATION WITH STANDARD KYPROLIS. IN ARM 2, IT WILL STUDY THE SAFETY AND EFFICACY OF ADDING SARCLISA DOSES EVERY OTHER WEEK IN COMBINATION WITH WEEKLY KYPROLIS AND DEXAMETHASONE. AFTER COMPLETION OF STUDY TREATMENT, PATIENTS ARE FOLLOWED UP AT 30 AND 60 DAYS AND THEN EVERY 3 MONTHS FOR UP TO 3 YEARS.
Expenses $2,713,588
-
IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE FOR EACH AND EVERY PATIENT.
Expenses $19,263,463
As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Kathy GiustiKATHY GIUSTI
FOUNDER & DIRECTOR
- Total calculated
- $736,867
- From this org
- $736,667
- From related orgs
- $0
- Other
- $200
- Hours/week
- 30
Schedule J breakdown matched by us
- Base
- $0
- Bonus
- $120,000
- Other
- $616,667
- Deferred
- $200
- Nontaxable benefits
- $0
- Filer's total
- $736,867
-
Thomas ConheeneyTHOMAS CONHEENEY
CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Gerald McDougallGERALD MCDOUGALL
VICE CHAIRMAN
- Total calculated
- $0
- Hours/week
- 2
-
Kenneth Anderson MDKENNETH ANDERSON MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Karen AndrewsKAREN ANDREWS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Rodney GilmoreRODNEY GILMORE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
David LucchinoDAVID LUCCHINO
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Lori Tauber-MarcusLORI TAUBER-MARCUS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Hugh MartinHUGH MARTIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Susan MarvinSUSAN MARVIN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
William McKiernanWILLIAM MCKIERNAN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Michael MortimerMICHAEL MORTIMER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
David Parkinson MDDAVID PARKINSON MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Marie Pinizzotto MDMARIE PINIZZOTTO MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Adrian RosenkranzADRIAN ROSENKRANZ
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Steve Shak MDSTEVE SHAK MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Kimberly WhiteKIMBERLY WHITE
DIRECTOR
- Total calculated
- $0
- Hours/week
- 2
-
Michael AndreiniMICHAEL ANDREINI
PRESIDENT & CEO
- Total calculated
- $517,478
- From this org
- $494,070
- From related orgs
- $0
- Other
- $23,408
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $325,049
- Bonus
- $135,000
- Other
- $34,021
- Deferred
- $15,050
- Nontaxable benefits
- $8,358
- Filer's total
- $517,478
-
Robert MianiROBERT MIANI
TREASURER & CFO
- Total calculated
- $384,663
- From this org
- $359,867
- From related orgs
- $0
- Other
- $24,796
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $249,179
- Bonus
- $91,600
- Other
- $19,088
- Deferred
- $16,032
- Nontaxable benefits
- $8,764
- Filer's total
- $384,663
-
Karen DietzKAREN DIETZ
SECRETARY CAO & GENERAL COUNSEL
- Total calculated
- $294,161
- From this org
- $271,181
- From related orgs
- $0
- Other
- $22,980
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $202,155
- Bonus
- $48,000
- Other
- $21,026
- Deferred
- $12,994
- Nontaxable benefits
- $9,986
- Filer's total
- $294,161
-
Anne Quinn YoungANNE QUINN YOUNG
CHIEF MISSION OFFICER
- Total calculated
- $359,860
- From this org
- $341,011
- From related orgs
- $0
- Other
- $18,849
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $251,766
- Bonus
- $64,000
- Other
- $25,245
- Deferred
- $12,235
- Nontaxable benefits
- $6,614
- Filer's total
- $359,860
-
Peter KosaPETER KOSA
MIF MANAGING DIRECTOR
- Total calculated
- $463,255
- From this org
- $429,658
- From related orgs
- $0
- Other
- $33,597
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $274,116
- Bonus
- $115,000
- Other
- $40,542
- Deferred
- $12,400
- Nontaxable benefits
- $21,197
- Filer's total
- $463,255
-
George MulliganGEORGE MULLIGAN
CHIEF SCIENTIFIC OFFICER
- Total calculated
- $259,376
- From this org
- $233,560
- From related orgs
- $0
- Other
- $25,816
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $222,208
- Bonus
- $0
- Other
- $11,352
- Deferred
- $9,546
- Nontaxable benefits
- $16,270
- Filer's total
- $259,376
-
Mindy FlinnMINDY FLINN
VP OF DEVELOPMENT
- Total calculated
- $254,746
- From this org
- $227,153
- From related orgs
- $0
- Other
- $27,593
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $191,010
- Bonus
- $22,000
- Other
- $14,143
- Deferred
- $9,400
- Nontaxable benefits
- $18,193
- Filer's total
- $254,746
-
Christopher WilliamsCHRISTOPHER WILLIAMS
VP OF ALLIANCE MANAGEMENT
- Total calculated
- $257,953
- From this org
- $229,055
- From related orgs
- $0
- Other
- $28,898
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $196,652
- Bonus
- $22,000
- Other
- $10,403
- Deferred
- $9,480
- Nontaxable benefits
- $19,418
- Filer's total
- $257,953
-
Hearn ChoHEARN CHO
CHIEF MEDICAL OFFICER
- Total calculated
- $217,186
- From this org
- $208,833
- From related orgs
- $0
- Other
- $8,353
- Hours/week
- 32
Schedule J breakdown matched by us
- Base
- $154,682
- Bonus
- $38,000
- Other
- $16,151
- Deferred
- $8,353
- Nontaxable benefits
- $0
- Filer's total
- $217,186
-
Eva M LepistoEVA M LEPISTO
VP OF INFORMATICS
- Total calculated
- $215,518
- From this org
- $204,912
- From related orgs
- $0
- Other
- $10,606
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $184,438
- Bonus
- $10,000
- Other
- $10,474
- Deferred
- $9,620
- Nontaxable benefits
- $986
- Filer's total
- $215,518
-
Greg RubensteinGREG RUBENSTEIN
VP OF MARKETING
- Total calculated
- $241,996
- From this org
- $212,086
- From related orgs
- $0
- Other
- $29,910
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $176,261
- Bonus
- $21,000
- Other
- $14,825
- Deferred
- $8,807
- Nontaxable benefits
- $21,103
- Filer's total
- $241,996
-
Charles VolpeCHARLES VOLPE
DIRECTOR, PR & COMMUNCIATIONS
- Total calculated
- $196,055
- From this org
- $173,921
- From related orgs
- $0
- Other
- $22,134
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $148,543
- Bonus
- $14,000
- Other
- $11,378
- Deferred
- $0
- Nontaxable benefits
- $22,134
- Filer's total
- $196,055
-
Todd BrooksTODD BROOKS
SR DIRECTOR, DEVELOPMENT
- Total calculated
- $187,539
- From this org
- $179,543
- From related orgs
- $0
- Other
- $7,996
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $155,996
- Bonus
- $13,000
- Other
- $10,547
- Deferred
- $7,176
- Nontaxable benefits
- $820
- Filer's total
- $187,539
-
Heather SteigerHEATHER STEIGER
DIRECTOR, DIGITAL MARKETING
- Total calculated
- $186,021
- From this org
- $169,691
- From related orgs
- $0
- Other
- $16,330
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $147,199
- Bonus
- $13,000
- Other
- $9,492
- Deferred
- $0
- Nontaxable benefits
- $16,330
- Filer's total
- $186,021
-
Joanne PugliaJOANNE PUGLIA
SR DIRECTOR FINANCE, CONTROLLER
- Total calculated
- $195,996
- From this org
- $185,860
- From related orgs
- $0
- Other
- $10,136
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $151,600
- Bonus
- $17,600
- Other
- $16,660
- Deferred
- $7,437
- Nontaxable benefits
- $2,699
- Filer's total
- $195,996
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Form 990 of other organizations
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
- 4a · Severance or change-of-control payment
- 7 · Other non-fixed payments
Answered no
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 4A
- KATHY GIUSTI, FOUNDER AND FORMER CHIEF MISSION OFFICER, RECEIVED A $250,000 SEVERANCE PAYMENT IN HER 2022 W-2.
- PART I, LINE 7
- INDIVIDUALS INCLUDED IN SCHEDULE J, PART II RECEIVED A DISCRETIONARY BONUS DURING CALENDAR YEAR 2022, WHICH WAS INCLUDED IN COLUMN B(II) HEREIN AND IN THEIR 2022 FORM W-2, BOX 5, AS TAXABLE MEDICARE WAGES.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
$2,804,526
SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION
-
BETH ISRAEL DEACONESS MEDICAL CENTER
$632,000
SITE INVESTMENT GRANT, IMMUNOTHERAPY
-
SITE INVESTMENT GRANT, IMMUNOTHERAPY
-
$110,700
SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION
-
$86,996
SITE INVESTMENT GRANT, FELLOW
-
$67,500
FELLOW
-
$65,000
SITE INVESTMENT GRANT
-
SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION
-
SITE INVESTMENT GRANT
-
SITE INVESTMENT GRANT
The 10 largest by cash amount. The API serves every itemized grant.
Activities outside the United States
From Schedule F of this return, as filed.
- Offices (line 3c)
- 0
- Employees, agents and contractors (line 3c)
- 0
- Expenditures and investments (line 3c)
- $2,057,500
At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.
Activities by region (Part I)
| Region | Offices | Employees | Activity | Specific services | Expenditures |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | GRANTMAKING | — | $30,000 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | — | $27,500 |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | INVESTMENTS | — | $2,000,000 |
Grants to organizations, by region (Part II)
The purpose of each grant is not shown.
| Region | Cash grants | Manner of disbursement | Noncash assistance | Noncash description | Valuation |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | $30,000 | WIRE | $0 | — | — |
| NORTH AMERICA | $27,500 | WIRE | $0 | — | — |
- Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
- 2
- Other grantees (Part II line 3)
- 0
- Transferred property to a foreign corporation during the year (line 1)
- Yes
- Had an interest in a foreign trust (line 2)
- No
- Owned an interest in a foreign corporation (line 3)
- Yes
- Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
- No
- Owned an interest in a foreign partnership (line 5)
- No
- Had operations in or related to a boycotting country (line 6)
- No
Taxable family on this return
Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.
Disregarded entities
Part I: entities that legally are the filer and file no return of their own.
-
MYELOMA INVESTMENT FUND LLC
VENTURE PHILANTHROPY FUND · DE · income $2,627,469 · assets $19,892,015
Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
-
MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC
FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH · CT · income $6,154,809 · assets $2,589,106
Directly controlled by THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 30 October 2023
- IRS schema version
- 2022v5.0
- Source object
- 202313039349302071
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.